Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) have provided new hope for cancer patients, and in particular for patients with tumors that are immunologically active and classified as hot tumors. These tumors express antigenic and tumor microenvironment (TME) characteristics that make them potential candidates...

Descripción completa

Detalles Bibliográficos
Autores principales: de Britto Evangelista, Guilherme Ferreira, Figueiredo, Amanda Braga, de Barros e Silva, Milton José, Gollob, Kenneth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
T Cell-Targeted Approaches to Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327097/
https://www.ncbi.nlm.nih.gov/pubmed/35919497
http://dx.doi.org/10.1093/immadv/ltac008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327097/
https://www.ncbi.nlm.nih.gov/pubmed/35919497
http://dx.doi.org/10.1093/immadv/ltac008

Ejemplares similares